Search Results - "Kaufman, Keith D."

Metabolic syndrome: a clinical and molecular perspective by Moller, David E, Kaufman, Keith D

“…The metabolic syndrome is a cluster of interrelated common clinical disorders, including obesity, insulin resistance, glucose intolerance, hypertension, and…”
Get full text

A randomized, placebo-controlled study of the cardiovascular safety of the once-weekly DPP-4 inhibitor omarigliptin in patients with type 2 diabetes mellitus by Gantz, Ira, Chen, Menghui, Suryawanshi, Shailaja, Ntabadde, Catherine, Shah, Sukrut, O'Neill, Edward A, Engel, Samuel S, Kaufman, Keith D, Lai, Eseng

“…Omarigliptin is a once-weekly (q.w.) oral DPP-4 inhibitor that is approved for the treatment of patients with type 2 diabetes mellitus (T2DM) in Japan. To…”
Get full text

Rationale, design, and organization of a randomized, controlled Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) in patients with type 2 diabetes and established cardiovascular disease by Green, Jennifer B., MD, Bethel, M. Angelyn, MD, Paul, Sanjoy K., PhD, Ring, Arne, PhD, Kaufman, Keith D., MD, Shapiro, Deborah R., DrPH, Califf, Robert M., MD, Holman, Rury R., MB, ChB, FRCP

“…Sitagliptin, an oral dipeptidyl peptidase-4 inhibitor, lowers blood glucose when administered as monotherapy or in combination with other antihyperglycemic…”
Get full text

Efficacy and Safety of Sitagliptin in Patients With Type 2 Diabetes and ESRD Receiving Dialysis: A 54-Week Randomized Trial by Arjona Ferreira, Juan C., MD, Corry, Dalila, MD, Mogensen, Carl E., MD, Sloan, Lance, MD, Xu, Lei, PhD, Golm, Gregory T., PhD, Gonzalez, Edward J., BS, Davies, Michael J., PhD, Kaufman, Keith D., MD, Goldstein, Barry J., MD, PhD

“…Background Treatment with oral antihyperglycemic agents has not been well characterized in patients with type 2 diabetes and end-stage renal disease (ESRD)…”
Get full text

Safety and Tolerability of Sitagliptin in Type 2 Diabetes: Pooled Analysis of 25 Clinical Studies by Engel, Samuel S., Round, Elizabeth, Golm, Gregory T., Kaufman, Keith D., Goldstein, Barry J.

“…Introduction In a previous pooled analysis of 19 double-blind clinical studies conducted by Merck, which included data available as of July 2009 on 10,246…”
Get full text

Cardiovascular safety of sitagliptin in patients with type 2 diabetes mellitus: a pooled analysis by Engel, Samuel S, Golm, Gregory T, Shapiro, Deborah, Davies, Michael J, Kaufman, Keith D, Goldstein, Barry J

“…To compare the incidence of cardiovascular events and mortality in patients with type 2 diabetes mellitus treated with sitagliptin or non-sitagliptin…”
Get full text

Safety and tolerability of sitagliptin in clinical studies: a pooled analysis of data from 10,246 patients with type 2 diabetes by Williams-Herman, Debora, Engel, Samuel S, Round, Elizabeth, Johnson, Jeremy, Golm, Gregory T, Guo, Hua, Musser, Bret J, Davies, Michael J, Kaufman, Keith D, Goldstein, Barry J

“…In a previous pooled analysis of 12 double-blind clinical studies that included data on 6,139 patients with type 2 diabetes, treatment with sitagliptin, a…”
Get full text

Global photographic assessment of men aged 18 to 60 years with male pattern hair loss receiving finasteride 1 mg or placebo by Olsen, Elise A., MD, Whiting, David A., MD, Savin, Ronald, MD, Rodgers, Anthony, MS, Johnson-Levonas, Amy O., PhD, Round, Elizabeth, PhD, Rotonda, Jennifer, PhD, Kaufman, Keith D., MD

“…Background Finasteride (1 mg) has been shown to increase vertex hair growth in men aged 18 to 60 years with male pattern hair loss and to increase frontal…”
Get full text

A randomized, placebo-controlled clinical trial evaluating the safety and efficacy of the once-weekly DPP-4 inhibitor omarigliptin in patients with type 2 diabetes mellitus inadequately controlled by glimepiride and metformin by Lee, Seung-Hwan, Gantz, Ira, Round, Elizabeth, Latham, Melanie, O'Neill, Edward A, Ceesay, Paulette, Suryawanshi, Shailaja, Kaufman, Keith D, Engel, Samuel S, Lai, Eseng

“…Type 2 diabetes (T2D) is a progressive disease that often requires a patient to use multiple antihyperglycemic agents to achieve glycemic control with disease…”
Get full text

Randomized clinical trial of the safety and efficacy of sitagliptin and metformin co‐administered to Chinese patients with type 2 diabetes mellitus by Ji, Linong, Han, Ping, Wang, Xiaoyue, Liu, Jingdong, Zheng, Shaoxiong, Jou, Ying‐Ming, O'Neill, Edward A, Golm, Gregory T, Engel, Samuel S, Kaufman, Keith D, Shankar, R Ravi

“…Introduction The results of a clinical trial to evaluate the efficacy and safety of initial combination therapy with sitagliptin and metformin in Chinese…”
Get full text

Safety and tolerability of sitagliptin in patients with type 2 diabetes: a pooled analysis by Williams-Herman, Debora, Round, Elizabeth, Swern, Arlene S, Musser, Bret, Davies, Michael J, Stein, Peter P, Kaufman, Keith D, Amatruda, John M

“…Sitagliptin, a highly selective dipeptidyl peptidase-4 inhibitor, is the first in a new class of oral antihyperglycemic agents (AHAs) for the treatment of…”
Get full text

Effects of MK-0941, a Novel Glucokinase Activator, on Glycemic Control in Insulin-Treated Patients With Type 2 Diabetes by Meininger, Gary E, Scott, Russell, Alba, Maria, Shentu, Yue, Luo, Edmund, Amin, Himal, Davies, Michael J, Kaufman, Keith D, Goldstein, Barry J

“…OBJECTIVE: To assess the efficacy and safety of MK-0941, a glucokinase activator (GKA), when added to stable-dose insulin glargine in patients with type 2…”
Get full text

A phase IIa active-comparator-controlled study to evaluate the efficacy and safety of efinopegdutide in patients with non-alcoholic fatty liver disease by Romero-Gómez, Manuel, Lawitz, Eric, Shankar, R. Ravi, Chaudhri, Eirum, Liu, Jie, Lam, Raymond L.H., Kaufman, Keith D., Engel, Samuel S., Bruzone, Santiago Oscar, Coronel, Maria Jimena, Gruz, Fernando M., MacKinnon, Ignacio, George, Jacob, Muller, Kate, Lee, Samuel S., Caussy, Cyrielle, Petit, Jean Michel, Ari, Ziv Ben, Braun, Marius, Katchman, Helena, Lurie, Yoav, Veitsman, Ella, Zuckerman, Eli, Aghemo, Alessio, Basili, Stenfania, Fracanzani, Anna Ludovica, Pietrangelo, Antonello, Sacerdoti, David, Rubio Arce, Jose Francisco, de Guevara Cetina, Alma Laura Ladron, Chavez-Tapia, Norberto Carlos, Reyes, Eira Cerda, Pinzon Te, Lourdes Lol-Be, Baker, John R., Ngu, Jeffrey, Orr, David, Janczewska, Ewa, Matusik, Pawel, Stanislaw Sadurski, Maciej Murawski, Akinina, Anna Valerievna, Alpenidze, Diana Nodarievna, Bogomolov, Pavel, Ermakova, Polina Yurievna, Golovach, Albina V., Kim, Sang Gyune, Lee, Jin-Woo, Paik, Yong Han, Park, Jun Yong, Yeon, Jong Eun, Blasco, Victor Vargas, Madueno, Francisco Jose Tinahones, Panero, Jose Luis Calleja, Perez, Esther Molina, Romero-Gómez, Manuel, Cheng, Pin-Nan, Jeng, Wen-Juei, Liu, Chun-Jen, Akyuz, Filiz, Balaban, Hatice Yasemin, Basaranoglu, Metin, Demir, Tevfik, Idilman, Ramazan, Karakan, Tarkan, Gyrina, Olga, Kolesnikova, Olena Vadimivna, Pyvovar, Sergiy M., Oliinyk, Oleksandr, Skrypnyk, Igor, Bassan, Isaac, Bowman, William Kelly, Denham, Douglas Scott, Ghalib, Reem, Lawitz, Eric J., Lucas, Kathryn Jean, Mohseni, Rizwana H., Sanchez, William Eduardo, Vierling, John Moore

“…This study assessed the effects of the glucagon-like peptide-1 (GLP-1)/glucagon receptor co-agonist efinopegdutide relative to the selective GLP-1 receptor…”
Get full text

Assessing the Safety of Sitagliptin in Older Participants in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) by Bethel, M Angelyn, Engel, Samuel S, Green, Jennifer B, Huang, Zhen, Josse, Robert G, Kaufman, Keith D, Standl, Eberhard, Suryawanshi, Shailaja, Van de Werf, Frans, McGuire, Darren K, Peterson, Eric D, Holman, Rury R

“…Limited data exist regarding safety and efficacy of antihyperglycemic drugs in older patients with type 2 diabetes. The Trial Evaluating Cardiovascular…”
Get full text

A randomized clinical trial of the efficacy and safety of sitagliptin compared with dapagliflozin in patients with type 2 diabetes mellitus and mild renal insufficiency: The CompoSIT‐R study by Scott, Russell, Morgan, Jerry, Zimmer, Zachary, Lam, Raymond L. H., O'Neill, Edward A., Kaufman, Keith D., Engel, Samuel S., Raji, Annaswamy

“…Aim To compare the efficacy and safety of the dipeptidyl peptidase‐4 inhibitor sitagliptin with the sodium‐glucose transporter‐2 inhibitor dapagliflozin in…”
Get full text

Efficacy and Safety of Sitagliptin Versus Glipizide in Patients With Type 2 Diabetes and Moderate-to-Severe Chronic Renal Insufficiency by CAMILO ARJONA FERREIRA, Juan, MARRE, Michel, BARZILAI, Nir, HUA GUO, GOLM, Gregory T, SISK, Christine Mccrary, KAUFMAN, Keith D, GOLDSTEIN, Barry J

“…Patients with type 2 diabetes mellitus (T2DM) and chronic kidney disease have an increased risk of micro- and macrovascular disease, but limited options for…”
Get full text

Cluster Analysis of Cardiovascular Phenotypes in Patients With Type 2 Diabetes and Established Atherosclerotic Cardiovascular Disease: A Potential Approach to Precision Medicine by Sharma, Abhinav, Zheng, Yinggan, Ezekowitz, Justin A, Westerhout, Cynthia M, Udell, Jacob A, Goodman, Shaun G, Armstrong, Paul W, Buse, John B, Green, Jennifer B, Josse, Robert G, Kaufman, Keith D, McGuire, Darren K, Ambrosio, Giuseppe, Chuang, Lee-Ming, Lopes, Renato D, Peterson, Eric D, Holman, Rury R

“…Phenotypic heterogeneity among patients with type 2 diabetes mellitus (T2DM) and atherosclerotic cardiovascular disease (ASCVD) is ill defined. We used cluster…”
Get full text

Causes of Death in a Contemporary Cohort of Patients With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease: Insights From the TECOS Trial by Sharma, Abhinav, Green, Jennifer B, Dunning, Allison, Lokhnygina, Yuliya, Al-Khatib, Sana M, Lopes, Renato D, Buse, John B, Lachin, John M, Van de Werf, Frans, Armstrong, Paul W, Kaufman, Keith D, Standl, Eberhard, Chan, Juliana C N, Distiller, Larry A, Scott, Russell, Peterson, Eric D, Holman, Rury R

“…We evaluated the specific causes of death and their associated risk factors in a contemporary cohort of patients with type 2 diabetes and atherosclerotic…”
Get full text

Corifollitropin Alfa Combined With Human Chorionic Gonadotropin in Adolescent Boys With Hypogonadotropic Hypogonadism by Shankar, R Ravi, Shah, Suneri, Joeng, Hee-Koung, Mendizabal, Geraldine, DiBello, Julia R, Guan, Yanfen, Stegmann, Barbara J, Nieschlag, Eberhard, Behre, Hermann M, Swerdloff, Ronald S, Fox, Michelle C, Kaufman, Keith D

“…Adolescent males with hypogonadotropic hypogonadism (HH) have traditionally been treated with exogenous testosterone (T) or human chorionic gonadotropin (hCG)…”
Get full text

Efficacy and safety of ipragliflozin in Japanese patients with type 2 diabetes and inadequate glycaemic control on sitagliptin by Kaku, Kohei, Kadowaki, Takashi, Seino, Yutaka, Okamoto, Taro, Shirakawa, Masayoshi, Sato, Asako, O'Neill, Edward A., Engel, Samuel S., Kaufman, Keith D.

“…Aims To assess the efficacy, safety and tolerability of ipragliflozin 50 mg once daily added to sitagliptin 50 mg once daily monotherapy in Japanese patients…”
Get full text